STOCK TITAN

Alector (ALEC) Form 144 Discloses RSU Vesting and Planned Sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Alector, Inc. (ALEC) filing of Form 144 reports an intended sale of 15,426 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $36,251.10. The filing shows approximately 101,212,329 shares outstanding and lists an approximate sale date of 09/02/2025.

The securities were acquired on 08/29/2025 by vesting of restricted stock units (30378 units originally noted) with payment dated 08/29/2025. The filer also disclosed a prior sale: 11,158 shares sold on 06/02/2025 for gross proceeds of $14,933.87. The notice contains the standard representation that the seller is not aware of undisclosed material adverse information.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine Rule 144 disclosure for an insider sale; size is small relative to outstanding shares and follows RSU vesting.

The Form 144 shows an intended disposition of 15,426 shares with a stated aggregate market value of $36,251.10 and an approximate sale date of 09/02/2025. The securities were acquired by RSU vesting on 08/29/2025 (30,378 units referenced), indicating this is a post-vesting sale of newly acquired shares rather than a purchase or loan-funded transaction. A prior sale of 11,158 shares on 06/02/2025 for $14,933.87 is also disclosed. From a market-impact perspective, the disclosed amounts are modest relative to the 101,212,329 shares outstanding reported in the filing.

TL;DR: Filing appears compliant with Rule 144 disclosure requirements; includes broker and acquisition details.

The notice identifies the broker (Morgan Stanley Smith Barney LLC) and provides the acquisition method as vesting of restricted stock units on 08/29/2025, which aligns with customary disclosure practices for insider-derived shares. The filing contains the required representation regarding material nonpublic information. There are no statements in the filing indicating any unusual arrangements or exceptions to standard Rule 144 requirements.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed for ALEC report?

The Form 144 reports an intended sale of 15,426 shares of Alector common stock with an aggregate market value of $36,251.10 and an approximate sale date of 09/02/2025.

How were the securities being sold acquired according to the filing?

The securities were acquired by vesting of restricted stock units on 08/29/2025, with 30,378 units noted as acquired.

Who is the broker handling the sale listed in the filing?

The broker listed is Morgan Stanley Smith Barney LLC, Executive Services located at the address provided in the filing.

Did the filer disclose any prior sales of ALEC stock?

Yes. The filer disclosed a prior sale of 11,158 shares on 06/02/2025 for gross proceeds of $14,933.87.

How many shares outstanding does the filing list for ALEC?

The filing lists 101,212,329 shares outstanding.
Alector

NASDAQ:ALEC

ALEC Rankings

ALEC Latest News

ALEC Latest SEC Filings

ALEC Stock Data

210.66M
98.25M
10.37%
77.1%
5.36%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO